Cargando…

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

SIMPLE SUMMARY: Since the irruption of PARPi in the therapeutic armamentarium for ovarian cancer, concerns regarding post-progression treatment outcomes have emerged, owing to known crossed-resistance mechanisms between PARPi and platinum. In this multicentric retrospective series of ovarian cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romeo, Margarita, Gil-Martín, Marta, Gaba, Lydia, Teruel, Iris, Taus, Álvaro, Fina, Claudia, Masvidal, Maria, Murata, Paola, Fernández-Plana, Julen, Martínez, Alejandro, Pérez, Cristina, García, Yolanda, Rodriguez, Valerie, Cros, Sara, Parera, Marta, Zanui, Montserrat, Catot, Silvia, Pardo, Beatriz, Plaja, Andrea, Esteve, Anna, Barretina-Ginesta, Maria Pilar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497128/ https://www.ncbi.nlm.nih.gov/pubmed/36139574 http://dx.doi.org/10.3390/cancers14184414

Ejemplares similares

Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery
por: Plaja, Andrea, et al.
Publicado: (2023)

Rare ovarian tumours. Other treatments for ovarian cancer
por: Gil-Martin, Marta, et al.
Publicado: (2020)

DNA damaging agents in ovarian cancer
por: Barretina-Ginesta, Maria-Pilar
Publicado: (2020)

SEOM-GEICO clinical guidelines on endometrial cancer (2021)
por: Barretina-Ginesta, María Pilar, et al.
Publicado: (2022)

Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus
por: Redondo, Andrés, et al.
Publicado: (2023)

Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients
por: Halvorsen, Ann Rita, et al.
Publicado: (2017)

Biological insights in non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
por: Alonso, Vicente, et al.
Publicado: (2018)

Prospective Biomarker Study in Advanced RAS Wild‐Type Colorectal Cancer: POSIBA Trial (GEMCAD 10‐02)
por: García‐Albéniz, Xabier, et al.
Publicado: (2019)

Esophageal Infiltration by High-Grade Serous Ovarian Carcinoma: A Very Rare Case Report
por: Carbó-Bagué, Anna, et al.
Publicado: (2023)

Management of advanced ovarian cancer in Spain: an expert Delphi consensus
por: Redondo, Andres, et al.
Publicado: (2021)

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
por: Barcellini, Amelia, et al.
Publicado: (2021)

Accumulated incidence of falls in people hospitalised with cancer and related factors
por: Martí‐Dillet, Maria Montserrat, et al.
Publicado: (2023)

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
por: Pignochino, Ymera, et al.
Publicado: (2017)

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

Different regulation of PARP1, PARP2, PARP3 and TRPM2 genes expression in acute myeloid leukemia cells
por: Gil-Kulik, Paulina, et al.
Publicado: (2020)

Do primary and secondary care doctors have a different experience and perception of cross-level clinical coordination? Results of a cross-sectional study in the Catalan National Health System (Spain)
por: Esteve-Matalí, Laura, et al.
Publicado: (2020)

Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor
por: Romeo, Margarita, et al.
Publicado: (2013)

Erratum to: Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor
por: Romeo, Margarita, et al.
Publicado: (2016)

Historical Review of Studies on Sacroiliac Fatty Nodules (Recently Termed “Back Mice”) as a Potential Cause of Low Back Pain
por: Cañis Parera, Marta, et al.
Publicado: (2021)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Are PARPs promiscuous?
por: Feijs, Karla L.H., et al.
Publicado: (2022)

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine
por: Murata, Stephen, et al.
Publicado: (2016)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)

The Role of Emotions in Classroom Conflict Management. Case Studies Geared Towards Improving Teacher Training
por: Alvarez, Ibis M., et al.
Publicado: (2022)

Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3
por: Sherstyuk, Yuliya V., et al.
Publicado: (2019)

The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study
por: Fernández-Serra, Antonio, et al.
Publicado: (2023)

Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
por: Moreno, Victor, et al.
Publicado: (2021)

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
por: Lahiguera, Álvaro, et al.
Publicado: (2020)

Mono-ADP-ribosylation by PARP10 and PARP14 in genome stability
por: Dhoonmoon, Ashna, et al.
Publicado: (2023)

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
por: Langelier, Marie-France, et al.
Publicado: (2023)

PARP-1 deregulation in multiple sclerosis
por: Meira, Maria, et al.
Publicado: (2019)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)
por: Rubio, María Jesús, et al.
Publicado: (2020)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

ADP-ribosyltransferases Parp1 and Parp7 safeguard pluripotency of ES cells
por: Roper, Stephen J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4ofm1s6tkdd83trfcs5smu5hev